Antianginal
Antianginal
Main page
A

Antianginal

logo
Community Hub0 subscribers
Read side by side
Antianginal
View on Wikipedia
from Wikipedia

An antianginal is a drug used in the treatment of angina pectoris, a symptom of ischaemic heart disease.

Examples

[edit]

Drugs used are nitrates, beta blockers, or calcium channel blockers.

Nitrates

[edit]
Main article: Nitrovasodilator

Nitrates cause vasodilation[1] of the venous capacitance vessels by stimulating the endothelium-derived relaxing factor (EDRF). Used to relieve both exertional and vasospastic angina by allowing venous pooling, reducing the pressure in the ventricles and so reducing wall tension and oxygen requirements in, the heart. Short-acting nitrates are used to abort angina attacks that have occurred, while longer-acting nitrates are used in the prophylactic management of the condition.

Agents include glyceryl trinitrate (GTN), pentaerythritol tetranitrate, isosorbide dinitrate and isosorbide mononitrate.

Beta blockers

[edit]

Beta blockers are used in the prophylaxis[2] of exertional angina by reducing the myocardial oxygen demand below the level that would provoke an angina attack.

They are contraindicated in variant angina and can precipitate heart failure. They are also contraindicated in severe asthmatics due to bronchoconstriction, and should be used cautiously in diabetics as they can mask symptoms of hypoglycemia.

Agents include either cardioselectives such as acebutolol or metoprolol, or non-cardioselectives such as oxprenolol or sotalol.

Calcium channel blockers

[edit]

Calcium ion (Ca++) antagonists (Calcium channel blockers) are used in the treatment of chronic stable angina, and most effectively in the treatment of variant angina (directly preventing coronary artery vasospasm). They are not used in the treatment of unstable angina .

In vitro, they dilate the coronary and peripheral arteries and have negative inotropic and chronotropic effects - decreasing afterload, improving myocardial efficiency, reducing heart rate and improving coronary blood flow. In vivo, the vasodilation and hypotension trigger the baroreceptor reflex. Therefore, the net effect is the interplay of direct and reflex actions.

  • Class I agents have the most potent negative inotropic effect and may cause heart failure.
  • Class II agents do not depress conduction or contractility.
  • Class III agent has negligible inotropic effect and causes almost no reflex tachycardia.

Examples include Class I agents (e.g., verapamil), Class II agents (e.g., amlodipine,[3] nifedipine), or the Class III agent diltiazem.

Nifedipine is more a potent vasodilator and more effective in angina. It is in the class of dihydropyridines and does not affect refractory period on SA node conduction.

References

[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Antianginal

View on Grokipedia
from Grokipedia
Antianginal drugs, also known as antianginal medications, are a class of pharmacological agents used to treat and prevent angina pectoris, a symptom of coronary artery disease characterized by chest pain or discomfort due to inadequate blood flow and oxygen supply to the heart muscle.[1] These drugs primarily function by either enhancing myocardial oxygen supply through vasodilation or reducing oxygen demand by decreasing heart rate, contractility, or preload, thereby alleviating symptoms and improving exercise tolerance in patients with stable ischemic heart disease.[2] The most commonly prescribed antianginal drugs fall into several key classes, each targeting different physiological mechanisms to manage angina effectively. Beta-blockers, such as metoprolol, reduce heart rate and blood pressure to lower the heart's oxygen requirements and have demonstrated benefits in reducing mortality among patients with reduced left ventricular function.[1][2] Nitrates, including nitroglycerin, act as vasodilators to relax and widen blood vessels, increasing blood flow to the heart and relieving acute episodes of angina, though long-term use may lead to tolerance.[1] Calcium channel blockers, like amlodipine or diltiazem, inhibit calcium influx in cardiac and vascular smooth muscle cells to dilate arteries and reduce myocardial workload, providing symptom relief without a clear survival advantage.[2] Additionally, ranolazine inhibits late sodium currents in cardiac cells to decrease ischemia without significantly affecting heart rate or blood pressure, often used as an add-on therapy for chronic stable angina when first-line agents are insufficient.[1][2] In clinical practice, antianginal therapy is recommended as a cornerstone of optimal medical management for stable angina, often combined with lifestyle modifications, antiplatelet agents like aspirin, and statins to address underlying atherosclerosis and reduce cardiovascular risk.[1] Guidelines from organizations such as the American College of Cardiology endorse these agents as first-line treatments, emphasizing individualized selection based on patient comorbidities, with all major classes showing comparable efficacy in symptom control and exercise capacity improvement.[2] While effective for symptom management, these drugs do not cure the underlying coronary disease, and ongoing research continues to evaluate their roles in long-term outcomes and novel combinations.[2]

Definition and Background

Definition of Antianginal Agents

Antianginal agents are a class of pharmacological treatments designed to prevent or alleviate angina pectoris, which manifests as chest pain resulting from myocardial ischemia due to reduced blood flow in ischemic heart disease.[3] These medications target the symptoms of coronary artery insufficiency by modulating factors that influence cardiac function and patient tolerance to physical exertion.[3] The primary objective of antianginal agents is to restore the equilibrium between myocardial oxygen supply and demand, thereby mitigating ischemic episodes and improving quality of life for affected individuals.[3] This balance is achieved through mechanisms that either enhance delivery of oxygen to the heart muscle or decrease its consumption, without directly addressing underlying atherosclerotic lesions.[4] The nomenclature "antianginal" stems from the prefix "anti-" denoting opposition, paired with "angina," a term rooted in ancient descriptions of strangling chest pain, underscoring the drugs' role in counteracting this symptom.[5] Pioneering examples, such as nitrates, emerged in the late 19th century, with amyl nitrite first employed for angina relief in 1867 and nitroglycerin introduced in 1879, marking the inception of targeted pharmacotherapy for this condition.[6] In scope, antianginal agents include vasodilators that promote coronary dilation to boost oxygen supply, demand-reducing agents that lower cardiac workload, and metabolic agents that shift energy utilization pathways in the myocardium to enhance efficiency during ischemia, explicitly excluding surgical or interventional therapies.[3]

Overview of Angina Pectoris

Angina pectoris is a clinical syndrome characterized by paroxysmal chest pain or discomfort resulting from transient myocardial ischemia, typically triggered by physical exertion, emotional stress, or other factors that increase myocardial oxygen demand.[7][8] This condition arises primarily as a symptom of underlying coronary artery disease (CAD), where atherosclerotic plaques narrow the coronary arteries, limiting blood flow to the heart muscle during periods of increased demand.[8][9] The classic presentation involves substernal pressure, tightness, or squeezing sensation in the chest, often radiating to the left arm, shoulder, jaw, neck, or back, with episodes typically lasting 2 to 10 minutes.[7][8] Accompanying symptoms may include shortness of breath, nausea, fatigue, or sweating, and the discomfort is usually relieved promptly by rest or sublingual nitroglycerin.[7][9] Women and older adults may experience atypical symptoms, such as epigastric discomfort or isolated jaw pain, which can complicate recognition.[10] Epidemiologically, angina pectoris affects millions worldwide, with an estimated prevalence of 2% to 7% in adults, rising sharply with age and cardiovascular risk factors such as hypertension, diabetes mellitus, smoking, hyperlipidemia, and obesity.[11][9] In the United States alone, approximately 10 million individuals experience angina, with about 500,000 new cases annually, and it serves as a major precursor to myocardial infarction, particularly in its unstable form.[9] Prevalence is higher among males and those over 40 years, though rates have shown some decline in recent decades due to improved risk factor management.[12][13] Diagnosis relies primarily on a detailed patient history of symptom characteristics, triggers, and relieving factors, supplemented by electrocardiographic (ECG) evidence of ischemia, such as ST-segment depression during episodes, and provocative testing like exercise stress testing to reproduce symptoms under controlled conditions.[14][1] Additional imaging, such as coronary computed tomography angiography, may confirm CAD extent but is guided by initial clinical assessment to stratify risk.[15] Antianginal agents play a key role in managing these symptoms to improve quality of life and reduce ischemic events.[9]

Pathophysiology of Angina

Myocardial Oxygen Imbalance

Myocardial oxygen imbalance forms the fundamental pathophysiological basis of angina pectoris, occurring when the heart muscle's oxygen requirements exceed the available supply, leading to ischemia. This mismatch is exacerbated during physical exertion or emotional stress, when demand rises sharply while supply may be constrained.[16] The primary determinants of myocardial oxygen supply include coronary perfusion pressure, the duration of diastole, and the oxygen-carrying capacity of blood. Coronary perfusion pressure, defined as the gradient between aortic diastolic pressure and left ventricular end-diastolic pressure, drives blood flow through the coronary arteries to deliver oxygen to the myocardium.[17] The duration of diastole is critical because coronary blood flow predominantly occurs during this phase, as systolic contraction compresses intramural vessels; shorter diastolic periods, often due to tachycardia, reduce perfusion time and thus oxygen delivery.[18] Additionally, the oxygen-carrying capacity depends on hemoglobin concentration and arterial oxygen saturation, with hemoglobin binding approximately 98% of transported oxygen, ensuring adequate delivery under normal conditions.[16] In contrast, myocardial oxygen demand is governed by heart rate, myocardial contractility, and ventricular wall tension. Heart rate influences demand by determining the frequency of contractions and the proportion of time spent in systole versus diastole, while increased contractility elevates energy requirements for force generation.[16] Wall tension, a major component, follows Laplace's law for thin-walled structures, where wall stress (σ\sigma) is calculated as:
σ=P×r2h \sigma = \frac{P \times r}{2h}
with PP as intraventricular pressure, rr as ventricular radius, and hh as wall thickness; thus, larger ventricular size or higher pressure amplifies tension and oxygen needs.[19] Ischemia manifests when oxygen demand surpasses supply, shifting metabolism to anaerobic glycolysis, which results in lactate accumulation and a drop in intracellular pH, ultimately triggering anginal pain through stimulation of cardiac nociceptors.[20] In the context of coronary atherosclerosis, fixed stenoses—typically narrowing the artery lumen by 70% or more—severely limit maximal coronary blood flow and abolish flow reserve, making the myocardium vulnerable to ischemia even with modest increases in demand during stress.[21]

Classification of Angina Types

Angina pectoris is classified into distinct types based on its underlying etiology, clinical presentation, duration, and triggers, which inform risk stratification and management strategies. These classifications stem from the recognition that myocardial oxygen supply-demand imbalance manifests differently across patient subgroups, though the core pathophysiology involves ischemia. The primary categories are stable angina, unstable angina, variant (Prinzmetal's) angina, and microvascular angina.[22] Stable angina represents the most common form, featuring predictable episodes of chest pain or discomfort induced by physical exertion, emotional stress, or other increases in myocardial oxygen demand, typically lasting a few minutes and resolving with rest or short-acting nitrates. It arises from fixed atherosclerotic stenoses in the epicardial coronary arteries, which restrict blood flow and prevent adequate vasodilation during heightened demand. Severity is assessed using the Canadian Cardiovascular Society (CCS) grading system, which categorizes symptoms based on the degree of activity limitation:
  • Class I: Angina with strenuous or prolonged exertion only; ordinary physical activity, such as walking or climbing stairs, does not provoke symptoms.
  • Class II: Slight limitation; angina occurs with walking more than two blocks on level ground or climbing more than one flight of stairs at a normal pace under normal conditions.
  • Class III: Marked limitation; angina develops after walking one or two blocks on level ground or climbing one flight of stairs at a normal pace.
  • Class IV: Severe limitation; inability to carry on any physical activity without discomfort, with symptoms possibly occurring at rest.
This grading aids in evaluating functional impact and guiding interventions.[9][23] Unstable angina is characterized by sudden new-onset angina, progressively worsening stable angina, or angina occurring at rest or with minimal exertion, often lasting longer than 10-20 minutes and less responsive to rest or nitrates. It results from atherosclerotic plaque rupture or erosion leading to non-occlusive thrombus formation, reducing coronary blood flow without complete occlusion. As a component of acute coronary syndrome, unstable angina carries a substantially elevated risk of myocardial infarction or death, with approximately 11% of patients experiencing these events within 12 months.[24] Variant angina, also known as Prinzmetal's or vasospastic angina, involves episodic coronary artery vasospasm that transiently occludes blood flow, typically provoking severe chest pain at rest, often between midnight and early morning, with episodes following a recurrent pattern. Unlike other forms, it frequently shows transient ST-segment elevation on electrocardiography during attacks, reflecting transmural ischemia, and occurs in patients with or without underlying atherosclerosis. Vasospasm is the primary etiology, distinguishing it from fixed obstructions.[22][25] Microvascular angina, sometimes termed cardiac syndrome X, stems from dysfunction or impaired vasodilation in the coronary microvasculature (arteries <500 μm in diameter), causing ischemia despite patent epicardial coronary arteries visible on angiography. Symptoms include prolonged chest pain, which may occur at rest or with exertion and persist beyond 10-30 minutes, often inadequately relieved by standard therapies. This type is more prevalent in women and highlights the role of small-vessel pathology in angina without macrovascular disease.[22][26]

General Mechanisms of Action

Enhancing Oxygen Supply

Antianginal agents enhance myocardial oxygen supply primarily through coronary vasodilation, which dilates the coronary arteries and increases blood flow to ischemic myocardial regions, thereby alleviating subendocardial ischemia. This mechanism improves oxygen delivery to areas of the heart muscle that are vulnerable during periods of increased demand, such as exercise, by augmenting perfusion across stenotic lesions without necessarily altering overall cardiac workload.[27] Venodilation represents another key aspect of oxygen supply enhancement, as it reduces venous return to the heart, thereby decreasing preload and ventricular filling pressures. By lowering end-diastolic volume, this effect indirectly supports myocardial oxygenation by mitigating wall tension in the left ventricle, which can otherwise exacerbate ischemia in compromised coronary circulation.[28] The nitric oxide (NO) pathway underlies much of this vasodilatory action, where NO release from endothelial cells or pharmacological sources activates guanylate cyclase in vascular smooth muscle, leading to increased cyclic guanosine monophosphate (cGMP) levels and subsequent relaxation of vessel walls. This pathway facilitates both coronary and peripheral vasodilation, promoting efficient oxygen transport to the myocardium.[28] However, these supply-enhancing mechanisms carry limitations, notably the potential for the coronary steal phenomenon, wherein vasodilation preferentially diverts blood flow away from collateral-dependent ischemic zones toward well-perfused areas, potentially worsening ischemia in regions reliant on such collaterals. This redistribution can undermine therapeutic efficacy in patients with heterogeneous coronary disease, highlighting the need for careful hemodynamic monitoring.[29]

Reducing Oxygen Demand

Reducing myocardial oxygen demand represents a primary therapeutic strategy in antianginal management, achieved by modulating key determinants of cardiac workload to restore the balance between oxygen supply and consumption. This approach targets the heart's energy expenditure during systole, where the majority of oxygen is utilized for contraction and pressure generation, thereby alleviating ischemia in patients with coronary artery disease. By lowering demand, these mechanisms help prevent or relieve anginal symptoms without necessarily increasing coronary blood flow, complementing strategies that enhance oxygen delivery.[27] Heart rate reduction plays a central role in decreasing oxygen demand by prolonging the duration of diastole relative to systole, which allows more time for coronary perfusion while reducing the overall frequency of contractions. Tachycardia shortens the diastolic phase, compressing the time available for myocardial filling and nutrient delivery, whereas a slower heart rate extends this period and lowers the number of cycles per minute, thereby diminishing total energy requirements. This effect is particularly beneficial during exertion, when elevated heart rates can exacerbate ischemia by outpacing supply.[30][31][32] Decreased myocardial contractility further contributes to reduced oxygen consumption by attenuating the force of ventricular contraction, which lowers the energy expended on shortening and pressure development. Contractility influences the velocity and extent of fiber shortening; a reduction in this parameter decreases the work performed per beat, conserving oxygen that would otherwise be used for forceful ejection against vascular resistance. This modulation ensures that the heart operates with less metabolic cost, especially under conditions of limited oxygen availability.[27][33] Afterload reduction, through arterial dilation, eases ventricular ejection by decreasing systemic vascular resistance, which reduces the pressure the heart must generate and aligns with implications from Starling's law by optimizing stroke volume for a given preload without excessive wall tension. Elevated afterload increases end-systolic volume and the energy required for pressure generation, whereas lowering it minimizes myocardial wall stress per the law of Laplace, thereby curtailing oxygen utilization. This mechanism is integral to workload modulation, as it directly impacts the impedance to outflow.[34][35] The integrated effects of these interventions culminate in a decrease in the rate-pressure product (RPP), calculated as heart rate multiplied by systolic blood pressure, serving as a reliable surrogate for overall myocardial oxygen demand. RPP reflects the combined influence of chronotropy and pressure load on cardiac work; reductions in either or both components lead to proportionally lower oxygen needs, providing a quantifiable index of therapeutic efficacy in clinical settings. This holistic decrease in demand helps maintain myocardial viability during ischemic episodes.[36][37]

Major Classes of Antianginal Drugs

Nitrates

Nitrates represent the prototypical class of antianginal drugs, primarily acting through vasodilation to alleviate symptoms of angina pectoris by improving the balance between myocardial oxygen supply and demand.[28] The historical use of nitrates for angina dates back to 1867, when amyl nitrite, an organic nitrite, was first employed as a therapeutic agent for the condition, later replaced by nitroglycerin—a byproduct of dynamite production—due to its more favorable administration and longer duration of effect.[38] Organic nitrates, such as nitroglycerin and isosorbide dinitrate, function by releasing nitric oxide (NO), which activates guanylate cyclase in vascular smooth muscle cells, elevating cyclic guanosine monophosphate (cGMP) levels and resulting in relaxation that preferentially dilates veins over arteries, thereby reducing preload and myocardial wall tension.[39][28] These agents are formulated in various delivery methods to suit acute and preventive needs: sublingual nitroglycerin provides rapid relief for acute attacks, while long-acting oral isosorbide dinitrate or transdermal nitroglycerin patches offer prophylaxis against recurrent episodes.[28][40] In terms of efficacy, sublingual administration achieves onset within 1 to 3 minutes, with effects lasting approximately 30 to 60 minutes, whereas long-acting formulations maintain therapeutic benefits for 3 to 5 hours, supporting extended symptom control during prophylaxis.[28][41] However, continuous exposure to nitrates leads to tolerance, typically developing within 12 to 24 hours, which diminishes their vasodilatory response and necessitates intermittent nitrate-free intervals of 10 to 12 hours to restore sensitivity.[28][40]

Beta-Blockers

Beta-blockers constitute a cornerstone of antianginal therapy by antagonizing beta-adrenergic receptors, which diminishes sympathetic stimulation to the heart and thereby lowers myocardial oxygen demand. Non-selective agents, such as propranolol, inhibit both β1 and β2 receptors, while cardioselective beta-blockers like metoprolol predominantly target β1 receptors in cardiac tissue, resulting in reduced heart rate (negative chronotropy) and contractility (negative inotropy). This blockade prevents catecholamine-induced increases in cardiac work, effectively alleviating ischemia in patients with exertional angina.[42][43] In clinical practice, beta-blockers are recommended as first-line therapy for stable angina pectoris, where they improve exercise tolerance and symptom control by modulating the imbalance between myocardial oxygen supply and demand. They are particularly beneficial in patients with concomitant hypertension or post-myocardial infarction, but should be avoided in vasospastic (Prinzmetal's) angina due to the risk of exacerbating coronary spasms through unopposed alpha-adrenergic activity.[44][25] Pharmacokinetically, beta-blockers are typically administered orally for chronic management, with dosing tailored to achieve heart rate control at rest (50-60 bpm) and during exertion. For example, metoprolol tartrate has a half-life of 3-7 hours, necessitating multiple daily doses, whereas the extended-release succinate formulation allows for once- or twice-daily regimens with a similar half-life of 3-7 hours; intravenous formulations are available for acute settings to rapidly reduce heart rate. Propranolol, with a half-life of approximately 4 hours, requires 3-4 daily doses.[45][42] Evidence from randomized controlled trials supports their efficacy, with beta-blockers reducing the frequency of angina episodes compared to placebo; for instance, propranolol has demonstrated reductions exceeding 50% in attack rates in longstanding studies. Meta-analyses confirm fewer weekly angina episodes with beta-blockers versus comparators like calcium channel blockers, alongside improved exercise capacity, though mortality benefits are more pronounced in patients with prior myocardial infarction.[46][47]

Calcium Channel Blockers

Calcium channel blockers (CCBs) represent a key class of antianginal agents that exert their effects by modulating calcium influx in cardiac and vascular tissues, thereby addressing both myocardial oxygen supply and demand imbalances. These drugs inhibit L-type voltage-gated calcium channels, preventing calcium entry into cells, which leads to relaxation of vascular smooth muscle and reduced cardiac contractility. In the context of angina pectoris, this dual action promotes coronary vasodilation to enhance oxygen delivery while decreasing myocardial workload through negative inotropic and chronotropic effects, particularly with certain subtypes.[48][49] CCBs are classified into two primary subtypes based on their chemical structure and predominant effects: non-dihydropyridines and dihydropyridines. Non-dihydropyridines, such as verapamil (a phenylalkylamine) and diltiazem (a benzothiazepine), exhibit stronger effects on cardiac conduction, providing rate control by slowing atrioventricular node conduction and reducing heart rate, which is beneficial in exertional angina. In contrast, dihydropyridines like amlodipine primarily target vascular smooth muscle, inducing potent peripheral and coronary vasodilation with minimal impact on heart rate, making them suitable for blood pressure management in ischemic heart disease.[48][49] In clinical practice, CCBs are particularly preferred for the management of variant (Prinzmetal's) angina, where coronary vasospasm predominates, as they effectively alleviate symptoms in approximately 90% of patients by counteracting spasm-induced ischemia. Combination therapy with beta-blockers is approached with caution, especially involving non-dihydropyridines, due to the risk of additive bradycardia and atrioventricular block in 10-15% of cases. For chronic therapy, long-acting formulations are favored to ensure steady-state efficacy and adherence; for example, amlodipine is typically dosed at 5-10 mg once daily, with the lower dose recommended for elderly patients or those with hepatic impairment.[25][50][51]

Emerging and Adjunctive Therapies

Metabolic Modulators

Metabolic modulators represent a class of antianginal agents that target myocardial energy metabolism to enhance cellular efficiency during ischemia, without significantly affecting heart rate or blood pressure. By optimizing the balance between oxygen supply and demand at the cellular level, these drugs promote a shift from less efficient fatty acid oxidation to more oxygen-sparing glucose metabolism, thereby reducing ischemic injury and improving tolerance to stress in patients with chronic stable angina. This approach is particularly useful as adjunctive therapy in cases where traditional agents like beta-blockers or calcium channel blockers provide incomplete symptom relief.[52][53] Ranolazine, a piperazine derivative, acts primarily as an inhibitor of the late sodium current (I_NaL) in cardiac myocytes, which accumulates during ischemia and leads to sodium-dependent calcium overload via the sodium-calcium exchanger. This overload impairs diastolic relaxation and exacerbates energy inefficiency; by blocking I_NaL, ranolazine reduces intracellular sodium and calcium levels, thereby decreasing diastolic dysfunction and shifting ATP production toward glucose oxidation over fatty acids. Clinical studies, such as the CARISA trial, have demonstrated that ranolazine, when added to standard therapy, reduces weekly angina episodes by approximately 23% and nitroglycerin use by 27% in patients with chronic angina, with greater benefits observed in those with more severe symptoms. In refractory angina registries, up to 43% of patients experience a two-class improvement in Canadian Cardiovascular Society (CCS) grading after one year of treatment, underscoring its role in symptom management without hemodynamic alterations. Ranolazine is approved by the FDA for chronic angina and is recommended as second-line add-on therapy in guidelines, though it is not indicated for acute coronary syndromes due to QT prolongation risks at higher doses.[54][55][56][57] Trimetazidine, a piperazine compound, inhibits 3-ketoacyl coenzyme A thiolase, a key enzyme in mitochondrial fatty acid β-oxidation, thereby partially blocking long-chain fatty acid utilization and favoring glucose oxidation for ATP generation during ischemic conditions. This metabolic switch enhances myocardial efficiency, as glucose oxidation yields more ATP per oxygen molecule consumed compared to fatty acids, without influencing contractility, heart rate, or vascular tone. Approved in Europe since 1978 and restricted in 2012 by the EMA to second-line add-on therapy for stable angina (excluding monotherapy or use in dizziness/vertigo), trimetazidine has been confirmed safe in recent assessments, including 2025 analyses emphasizing its tolerability in patients without Parkinsonian symptoms or severe renal impairment. Trials like VASCO and EMANON show it reduces angina attacks by 20-30% and improves exercise tolerance when combined with beta-blockers, positioning it as a guideline-endorsed option (ESC class IIa) for refractory symptoms, particularly in regions where it is available. Contraindications include Parkinson's disease due to potential extrapyramidal effects, and dosing adjustments are required for moderate renal dysfunction.[58][59][60][61][62]

Sinus Node Inhibitors

Sinus node inhibitors represent a targeted class of antianginal agents that selectively reduce heart rate by modulating the sinoatrial node's pacemaker activity, offering an alternative for patients intolerant to traditional heart rate-lowering therapies. Ivabradine, the primary agent in this class, acts by inhibiting the hyperpolarization-activated cyclic nucleotide-gated (HCN) channels responsible for the funny current (I_f) in the sinoatrial node, which slows the rate of diastolic depolarization without impacting myocardial contractility, blood pressure, or vascular tone.[63][64] This mechanism contributes to reduced myocardial oxygen demand, particularly beneficial in stable angina where heart rate elevation exacerbates ischemia.[65] Ivabradine is indicated as an add-on therapy for chronic stable angina in patients whose symptoms persist despite optimal beta-blocker treatment, or as monotherapy when beta-blockers are contraindicated, such as in cases of asthma, severe bradycardia, or advanced atrioventricular block.[66][67] The recommended starting dose is 5 mg twice daily, with upward titration to 7.5 mg twice daily after two weeks if tolerated and needed to achieve therapeutic heart rate reduction, administered with meals to enhance bioavailability.[68] Dosing adjustments are guided by regular heart rate assessments to avoid excessive bradycardia. The efficacy of ivabradine in angina management was demonstrated in the SIGNIFY trial, a large randomized study involving over 19,000 patients with stable coronary artery disease, where it reduced the frequency of angina attacks by approximately 20% in the subgroup with baseline angina, alongside a mean heart rate reduction of 10 beats per minute.[64] Current guidelines, including the 2024 European Society of Cardiology recommendations (applicable through 2025), endorse ivabradine with a Class IIa, Level B recommendation for add-on therapy in select patients with chronic coronary syndromes, left ventricular systolic dysfunction, resting heart rates ≥70 bpm, and persistent symptoms despite beta-blockers, or as monotherapy when beta-blockers are contraindicated.[67] A distinctive aspect of ivabradine therapy is the emphasis on individualized dosing through heart rate monitoring to target a resting rate of 55-60 beats per minute, which optimizes antianginal benefits while minimizing risks like symptomatic bradycardia; this may involve ambulatory or optical-based monitoring devices for precise titration in clinical practice.[69]

Clinical Applications and Guidelines

Indications and Patient Selection

Antianginal drugs are primarily indicated for the management of stable angina pectoris, where beta-blockers or calcium channel blockers (CCBs) serve as first-line therapies to alleviate symptoms and improve exercise tolerance by reducing myocardial oxygen demand.[44] In patients with stable angina, beta-blockers are particularly recommended for those with a history of myocardial infarction or left ventricular systolic dysfunction (ejection fraction ≤50%), as they decrease angina frequency and nitroglycerin use, supported by randomized controlled trials and meta-analyses.[44] CCBs, especially dihydropyridines, are suitable alternatives or adjuncts, particularly when beta-blockers are contraindicated, and long-acting nitrates are employed for breakthrough symptoms to provide rapid vasodilation and symptom relief.[44] For unstable angina, classified as part of acute coronary syndromes, immediate hospitalization is required, with antianginal therapy combined with antiplatelet agents to stabilize the patient and prevent progression to myocardial infarction.[70] According to the 2025 ACC/AHA guidelines, initial management includes anti-ischemic agents such as beta-blockers (unless contraindicated) and nitrates for ongoing ischemia, alongside dual antiplatelet therapy with aspirin and a P2Y12 inhibitor (ticagrelor or prasugrel preferred over clopidogrel) to reduce thrombotic risk.[71] Calcium channel blockers may be added for persistent symptoms if nitrates and beta-blockers are inadequate, emphasizing a multimodal approach during acute evaluation.[72] Patient selection for antianginal therapy must account for comorbidities to optimize safety and efficacy. Beta-blockers should be avoided or used cautiously in patients with chronic obstructive pulmonary disease (COPD), preferring cardioselective agents to minimize bronchospasm risk, as evidenced by meta-analyses showing no significant worsening of respiratory function in most cases.[73] Nitrates are contraindicated in hypotensive patients (systolic blood pressure <90 mmHg) due to the risk of severe vasodilation and hemodynamic instability.[28] In elderly patients, therapy selection prioritizes tolerability, often favoring CCBs over beta-blockers to reduce side effects like fatigue, with adjustments for polypharmacy and frailty through shared decision-making.[74] In refractory stable angina, where symptoms persist despite optimal monotherapy, combination therapy involving up to three antianginal agents—such as a beta-blocker plus a CCB and a nitrate—is recommended before considering revascularization, guided by the 2023 AHA/ACC chronic coronary disease guidelines (Class IIa recommendation).[44] This approach is tailored to individual response and comorbidities, with evidence from clinical trials demonstrating improved symptom control without excessive adverse events when titrated appropriately.[75]

Dosing Regimens and Administration

Antianginal therapy dosing begins with short-acting nitrates for acute symptom relief, typically administered as sublingual nitroglycerin at 0.3 to 0.6 mg every 5 minutes as needed, up to a maximum of three doses.[44] For prophylaxis, long-acting nitrates such as isosorbide mononitrate are initiated at 30 to 60 mg once daily, with a mandatory nitrate-free interval of 10 to 12 hours to prevent tolerance development.[44] Isosorbide dinitrate, another option, is dosed at 20 to 40 mg daily in divided doses, similarly incorporating a nitrate-free period.[44] Beta-blockers serve as first-line agents for ongoing antianginal management, with metoprolol tartrate commonly started at 25 to 50 mg twice daily, titrated gradually to 100 mg twice daily based on patient tolerance and response.[44] The extended-release formulation, metoprolol succinate, is administered at 25 to 200 mg once daily, aiming for a target resting heart rate of 50 to 60 beats per minute to optimize myocardial oxygen demand reduction.[44] Titration occurs every 1 to 2 weeks, monitoring for efficacy in symptom control and side effects such as bradycardia.[44] Effective monitoring of antianginal therapy involves regular assessment of electrocardiograms (ECGs) to establish a baseline and detect ischemic changes during symptoms, alongside blood pressure measurements targeting systolic values below 130 mm Hg.[44] Heart rate and symptom logs, using tools like the Seattle Angina Questionnaire, guide dose adjustments, with exercise tolerance evaluated via treadmill testing if symptoms persist or worsen despite optimization.[44] As of 2025, pharmacogenomic testing for CYP2D6 variants informs personalized beta-blocker dosing, particularly for metoprolol; poor metabolizers should avoid metoprolol if possible or initiate with a 25-50% dose reduction from the standard starting dose and titrate based on response, while intermediate metabolizers may initiate with the standard dose but require close monitoring for efficacy and adverse effects.[76] This approach enhances safety and efficacy in genetically susceptible patients.[76]

Adverse Effects and Safety Considerations

Common Side Effects by Class

Nitrates, such as nitroglycerin and isosorbide dinitrate, commonly cause side effects related to their vasodilatory action via nitric oxide (NO) release. The most frequent adverse reaction is headache, resulting from cerebral vasodilation mediated by NO, with an incidence reported in up to 82% of patients in placebo-controlled trials, though approximately 50% of initial users experience it, often resolving with continued use or dose adjustment.[77][78] Flushing and reflex tachycardia also occur due to peripheral and venous vasodilation, leading to compensatory sympathetic activation.[28] Nitrate tolerance, characterized by diminished therapeutic effect over time, is attributed to depletion of sulfhydryl groups necessary for NO biotransformation in vascular smooth muscle.[79] Beta-blockers, including agents like metoprolol and atenolol, exert their effects through non-selective or cardioselective adrenergic blockade, which can lead to several common side effects. Fatigue is prevalent, arising from reduced cardiac output and beta-2 mediated effects on skeletal muscle perfusion, affecting a significant portion of patients during chronic use.[42] Bradycardia results from unopposed parasympathetic tone and inhibition of sinoatrial node activity, often dose-dependent and more pronounced in susceptible individuals.[45] Non-selective beta-blockers, such as propranolol, may additionally provoke bronchospasm in patients with reactive airway disease due to beta-2 receptor antagonism in the lungs.[80] Calcium channel blockers (CCBs) vary in side effect profile by subclass, primarily due to differences in vascular versus cardiac selectivity. Dihydropyridines like amlodipine frequently cause peripheral edema from preferential arteriolar vasodilation leading to increased capillary hydrostatic pressure, with incidence rates up to 10-15% in clinical studies.[81] Non-dihydropyridine CCBs, such as verapamil, are associated with constipation from smooth muscle relaxation in the gastrointestinal tract, reported in up to 10% of users.[82] Both classes carry a risk of atrioventricular (AV) block, particularly verapamil and diltiazem, due to suppression of AV nodal conduction, though this is less common in dihydropyridines.[48]

Contraindications and Drug Interactions

Antianginal nitrates are absolutely contraindicated in patients with severe hypotension, as they can exacerbate hemodynamic instability through vasodilation.[28] Concomitant use with phosphodiesterase-5 (PDE5) inhibitors, such as sildenafil, is also strictly prohibited due to the risk of profound hypotension from synergistic vasodilation effects.[28] Additionally, nitrates should be avoided in conditions like right ventricular infarction, where preload reduction may lead to severe hypotension.[28] Beta-blockers are contraindicated in decompensated heart failure, as they can worsen cardiac output in unstable states, though they are beneficial in compensated chronic heart failure.[42] They are also contraindicated in patients with second- or third-degree atrioventricular (AV) block due to the risk of exacerbating conduction abnormalities and bradycardia.[42] A key drug interaction occurs with verapamil, a non-dihydropyridine calcium channel blocker, where the combination can potentiate bradycardia and AV block, necessitating careful monitoring or avoidance in susceptible patients.[42] Non-dihydropyridine calcium channel blockers (CCBs), such as verapamil and diltiazem, are contraindicated in systolic heart failure with reduced ejection fraction, as they may depress myocardial contractility and worsen outcomes.[48] Grapefruit juice inhibits CYP3A4 metabolism, leading to elevated CCB plasma levels and increased risk of toxicity, including hypotension and bradycardia; patients should be advised to avoid it.[48] Other CYP3A4 inhibitors, like erythromycin or azole antifungals, similarly elevate CCB concentrations, requiring dose adjustments or alternative therapies.[48] In elderly patients, 2025 clinical consensus statements emphasize vigilant monitoring for polypharmacy risks in antianginal therapy, as multimorbidity increases the likelihood of adverse drug reactions and interactions, particularly in those with heart failure.[83] This includes regular deprescribing reviews to minimize cumulative effects on hemodynamics and conduction in this vulnerable population.[83]

Historical Development

Early Discoveries

The recognition of angina pectoris as a distinct clinical entity began in the late 18th century, when British physician William Heberden described it in 1772 as a condition involving constricting chest pain often triggered by exertion, distinguishing it from neuralgic disorders and emphasizing its ischemic nature due to coronary artery insufficiency. This foundational insight shifted medical understanding toward vascular causes, though effective pharmacological treatments emerged only in the 19th century. A pivotal early discovery in antianginal therapy occurred in 1867, when Scottish physician Thomas Brunton administered amyl nitrite to patients with angina, observing rapid relief of symptoms through vasodilation. Brunton's work, detailed in his clinical reports, marked the first targeted use of a nitrate compound for angina, leveraging its ability to relax vascular smooth muscle and reduce cardiac preload. In 1879, William Murrell introduced nitroglycerin—originally synthesized for Alfred Nobel's dynamite production—as a treatment for angina, further establishing nitrates' role. Amyl nitrite was used as a convenient inhaled or sublingual agent for acute angina attacks since 1867, providing swift coronary vasodilation and symptom alleviation, building on the nitrate mechanism pioneered by Brunton. The mid-20th century saw a major advance with the introduction of beta-blockers, as propranolol—the first such agent—received approval for angina treatment in the United Kingdom in 1967. Developed by James Black and colleagues, propranolol worked by blocking beta-adrenergic receptors to reduce heart rate and myocardial oxygen demand, offering a non-vasodilatory approach that complemented nitrates and addressed the ischemic etiology highlighted by Heberden. Nitrates like nitroglycerin have maintained an enduring role in therapy since these early innovations.

Recent Advances up to 2025

In the 1980s, calcium channel antagonists such as nifedipine emerged as a key advancement for managing vasospastic angina, also known as Prinzmetal's angina, by effectively inhibiting coronary artery spasms and reducing ischemic episodes.[84] Early clinical studies demonstrated nifedipine's efficacy in preventing spasm-induced attacks, with reports from 1980 highlighting its role in stabilizing patients unresponsive to prior therapies like nitrates and beta-blockers.[85] The 2000s introduced novel metabolic and heart rate-modulating agents for refractory angina cases. Ranolazine received FDA approval on January 27, 2006, as an add-on therapy for chronic angina in patients inadequately controlled by other antianginals, targeting late sodium current inhibition to improve myocardial efficiency without significant hemodynamic changes.[86] Similarly, ivabradine was approved by the European Medicines Agency in 2005 for symptomatic treatment of chronic stable angina in patients with normal sinus rhythm, selectively reducing heart rate via inhibition of the If current to alleviate ischemia.[87] From the 2010s to 2025, landmark trials and guideline updates reinforced optimized medical therapy as a cornerstone over invasive strategies in stable ischemic heart disease. The ISCHEMIA trial, published in 2020, randomized 5,179 patients with moderate or severe ischemia to initial invasive (angiography and revascularization) versus conservative (medical therapy) strategies, finding no significant reduction in major cardiovascular events with routine stenting at a median follow-up of 3.2 years, thus supporting guideline-directed medical management as first-line.[88] The 2025 ACC/AHA guideline for acute coronary syndromes references studies on sodium-glucose cotransporter-2 (SGLT2) inhibitors post-myocardial infarction for preventing heart failure hospitalizations in patients with comorbid conditions and directs to the 2022 heart failure guideline for their use.[70] Emerging therapies include investigational gene-based approaches to enhance coronary vasodilation and perfusion in refractory angina. The EXACT phase 2 trial of XC001, an epicardial-delivered gene therapy expressing vascular endothelial growth factor (VEGF) to promote angiogenesis and vasodilation, reported sustained improvements in exercise tolerance, myocardial perfusion by PET imaging, and angina frequency at 12 months in no-option refractory angina patients (results published in 2024).[89] Trimetazidine continues to be used as an adjunct metabolic modulator for angina management in approved indications.[90]

References

  1. Angina - Diagnosis and treatment - Mayo Clinic
  2. Antianginal Agents for the Management of Stable Ischemic Heart ...
  3. Antiangina Pectoris Agent - an overview | ScienceDirect Topics
  4. Antianginal Drugs - CV Pharmacology
  5. ANTIANGINAL - Definition & Meaning - Reverso English Dictionary
  6. The Role of Nitroglycerin and Other Nitrogen Oxides in ... - JACC
  7. Angina (Chest Pain) | American Heart Association
  8. Angina - Symptoms and causes - Mayo Clinic
  9. Angina - StatPearls - NCBI Bookshelf - NIH
  10. Angina in Women Can Be Different From Men
  11. Prevalence of angina pectoris and association with coronary ... - NIH
  12. Prevalence of Angina Pectoris: An Analysis of the National Health ...
  13. A Decline in the Prevalence of Angina Pectoris - PubMed
  14. Evaluation and Management of Patients With Stable Angina
  15. 2021 AHA/ACC Chest Pain Guideline Perspectives
  16. Physiology, Myocardial Oxygen Demand - StatPearls - NCBI Bookshelf
  17. Coronary Perfusion Pressure - StatPearls - NCBI Bookshelf
  18. Prolonged Diastolic Time Fraction Protects Myocardial Perfusion ...
  19. The Myocardial Oxygen Supply:Demand Index Revisited
  20. Pathobiology of Myocardial Ischemia and Reperfusion Injury
  21. Recent advances in the management of chronic stable angina I
  22. Angina (Chest Pain) - Types - NHLBI - NIH
  23. Executive Summary of the Guidelines on Stable Coronary Disease
  24. Unstable Angina - StatPearls - NCBI Bookshelf - NIH
  25. Prinzmetal Angina - StatPearls - NCBI Bookshelf
  26. Angina in 2022: Current Perspectives - PMC - NIH
  27. https://pubmed.ncbi.nlm.nih.gov/29874661/
  28. https://pubmed.ncbi.nlm.nih.gov/26466065/
  29. Coronary Steal: Mechanisms of a Misnomer
  30. Anti-anginal and anti-ischemic effects of late sodium current inhibition
  31. Heart rate in the pathophysiology of coronary blood flow and ...
  32. The Myocardial Oxygen Supply:Demand Index Revisited - PMC
  33. Heart rate reduction after genetic ablation of L-type Cav1.3 channels ...
  34. Antianginal Actions of Beta-Adrenoceptor Antagonists - PMC
  35. Antianginal actions of beta-adrenoceptor antagonists - PubMed
  36. Physiology, Afterload Reduction - StatPearls - NCBI Bookshelf
  37. The Cardiac Cycle and the Physiological Basis of Left Ventricular ...
  38. Circadian rhythm of double (rate-pressure) product in ... - PubMed
  39. Association between Myocardial Oxygen Supply and Demand ... - NIH
  40. Nitrates - StatPearls - NCBI Bookshelf - NIH
  41. Nitrates and Nitrites in the Treatment of Ischemic Cardiac Disease
  42. The Role of Nitroglycerin and Other Nitrogen Oxides in ...
  43. Nitrate Therapy | Circulation - American Heart Association Journals
  44. [PDF] NITROSTAT (nitroglycerin) sublingual tablet - accessdata.fda.gov
  45. Beta Blockers - StatPearls - NCBI Bookshelf
  46. Mode of action of beta blockers in angina pectoris - PubMed
  47. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the ...
  48. Metoprolol - StatPearls - NCBI Bookshelf
  49. Advancements in Pharmacotherapy for Angina - PMC - NIH
  50. Meta-analysis of trials comparing beta-blockers, calcium antagonists ...
  51. Calcium Channel Blockers - StatPearls - NCBI Bookshelf
  52. Calcium Channel Blockers - PMC - NIH
  53. Combined use of calcium-channel and beta-adrenergic blockers for ...
  54. [PDF] Norvasc (amlodipine besylate) tablet label - accessdata.fda.gov
  55. Ranolazine: A Contemporary Review | Journal of the American ...
  56. https://www.ecrjournal.com/articles/trimetazidine-and-other-metabolic-modifiers
  57. Late Sodium Current Blocker (Ranolazine) - CV Pharmacology
  58. Mechanism of Action of Ranolazine | JAMA Internal Medicine
  59. The ERICA (Efficacy of Ranolazine in Chronic Angina) Trial | JACC
  60. Ranolazine: A Better Understanding of Its Pathophysiology and ...
  61. Trimetazidine - an overview | ScienceDirect Topics
  62. The Antianginal Drug Trimetazidine Shifts Cardiac Energy ...
  63. European Medicines Agency recommends restricting use of ...
  64. Additional and emerging drugs for standard therapy for patients with ...
  65. https://www.droracle.ai/articles/486672/what-is-the-safety-of-using-trimetazidine-metabolic-modulator
  66. Ivabradine: Uses, Interactions, Mechanism of Action | DrugBank Online
  67. Ivabradine in Stable Coronary Artery Disease without Clinical Heart ...
  68. Role of ivabradine in management of stable angina in patients with ...
  69. Ivabradine Anpharm | European Medicines Agency (EMA)
  70. https://academic.oup.com/eurheartj/article-lookup/doi/10.1093/eurheartj/ehae177
  71. Ivabradine - StatPearls - NCBI Bookshelf
  72. The Role of Ivabradine in the Management of Angina Pectoris - PMC
  73. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the ...
  74. 2025 Acute Coronary Syndromes Guideline-at-a-Glance - JACC
  75. ACC/AHA Guidelines for the Management of Patients With Unstable ...
  76. Beta-blockers use in patients with chronic obstructive pulmonary ...
  77. The Management of Stable Angina in the Older Adult Population - NIH
  78. Stable Angina Medical Therapy Management Guidelines - NIH
  79. CPIC® Guideline for Beta-blockers and CYP2D6, ADRB1, ADRB2 ...
  80. Side effects of using nitrates to treat angina - PubMed
  81. Headache‐type adverse effects of NO donors: vasodilation and ...
  82. Mechanisms of nitrate tolerance - PubMed - NIH
  83. Pharmacological treatment of chronic stable angina pectoris - PMC
  84. Side effects of calcium channel blockers.
  85. How to handle polypharmacy in heart failure. A clinical consensus ...
  86. Nifedipine in Ischemic Heart Disease | Circulation
  87. Pharmacotherapy of Vasospastic Angina
  88. Drug Approval Package: Ranexa (Ranolazine) NDA #021526
  89. Procoralan | European Medicines Agency (EMA)
  90. Initial Invasive or Conservative Strategy for Stable Coronary Disease
  91. Angiogenic Gene Therapy for Refractory Angina: Results of the ...
  92. Trimetazidine Use in Cardiovascular Disease - PubMed
User Avatar
No comments yet.